Why Republican Presidential Contenders Are Mostly Silent About Biden’s Signature Prescription Drug Policy
Donald Trump is more vocal than his GOP rivals, but he failed to pass a bill reducing drug costs while in office.
It's the first step in a process that will mean lower prices in 2026 ― unless the drug industry and its allies find a way to block it.
The Biden administration plans to name the first 10 Medicare drugs subject to price negotiation, while pharmaceutical companies try to block the effort in court.
This year's budget would increase payroll taxes for higher-income Americans, while strengthening the program's new power to negotiate drug prices.
The Vermont senator outlines his agenda for the Senate health, education, labor and pensions committee -- and explains why he thinks it can become reality.
Pharmaceutical companies Eisai and Biogen said they plan to publish the findings in a peer-reviewed medical journal.
Some of the most important work that went into Joe Biden’s new law took place before he even became president.
Some theories on why Republicans have so little to say about the sweeping, historic Democratic legislation on the verge of becoming law.
Since the fall of Roe, some pharmacies have refused to fill certain prescriptions that are the same as or similar to the drugs used in medication abortion.
Medicare negotiations for lower prescription prices have become the cornerstone of a new domestic policy bill.